Joshua F Yarrow, Christine F Conover, Sean C McCoy, Judyta A Lipinska, Cesar A Santillana, John M Hance, Darryl F Cannady, Tisha D VanPelt, Joshua Sanchez, Bryan P Conrad, Jennifer E Pingel, Thomas J Wronski, Stephen E Borst
Selective androgen receptor modulators (SARMs) now under development can protect against muscle and bone loss without causing prostate growth or polycythemia. 17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone), a potent testosterone analog, may have SARM-like actions because, unlike testosterone, trenbolone does not undergo tissue-specific 5α-reduction to form more potent androgens. We tested the hypothesis that trenbolone-enanthate (TREN) might prevent orchiectomy-induced losses in muscle and bone and visceral fat accumulation without increasing prostate mass or resulting in adverse hemoglobin elevations...
April 2011: American Journal of Physiology. Endocrinology and Metabolism